Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00060268 · ClinicalTrials.gov registry record · Phase 1

Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors

A Phase 1 study, sponsored by Roswell Park Cancer Institute.

Completed
Registry status
Phase 1
Development phase
11
Enrollment target

NCT00060268: Completed Phase 1 study, sponsored by Roswell Park Cancer Institute.

NCT00060268 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 11 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00060268, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.

COMPLETED
Registry status
Phase 1
Development phase
11 participants
Enrollment target

Study Summary

RATIONALE: Photodynamic therapy uses light and drugs that make tumor cells more sensitive to light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of photodynamic therapy with HPPH in treating patients who have obstructive esophageal tumors.

Interventions

  • DRUG HPPH

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 1997-01
Est. Completion 2004-06
Phase Phase 1
Roswell Park Cancer Institute

365 total trials

What the finished NCT00060268 record still lists

NCT00060268 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower).

The record links to 0 conditions, and to 1 intervention - of which HPPH is the first listed.

NCT00060268 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00060268 about?

NCT00060268 is a clinical study titled "Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors". RATIONALE: Photodynamic therapy uses light and drugs that make tumor cells more sensitive to light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells. PURPOSE: Phase I/II trial to study the effectiv...

What is the current status of trial NCT00060268?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 1997-01. Estimated completion is 2004-06.

What interventions are being tested in trial NCT00060268?

The interventions under investigation include: HPPH (DRUG).

Who is sponsoring clinical trial NCT00060268?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00060268's enrollment target sits among peer trials

11 1911th of 2000 higher than 88 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03114462 · 11 participants · Phase 1

    Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

  • NCT06039709 · 11 participants · Phase 1

    Sonodynamic Therapy in Patients With Recurrent GBM

  • NCT06425380 · 11 participants · NA

    Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

  • NCT06472661 · 11 participants · Early Phase 1

    FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00060268, the US trial registry maintained by the National Library of Medicine. NCT00060268 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.